ADC Landscape
Pfizer (Seagen)
CD30 · Hodgkin lymphoma, ALCL
ApprovedAntibody–Drug Conjugates
Target
CD30
Payload
MMAE
Payload class
Auristatin
Linker
Cleavable val-cit (mc-vc-PABC)
Indication
Hodgkin lymphoma, ALCL
Phase
Approved
Partner
Takeda (ex-US)
Overview
The ADC that proved the modern model. Seagen's val-cit/MMAE chemistry became the field's most-licensed toolkit — the foundation Pfizer paid $43B for.
Technology
Pfizer (Seagen) works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Roche / Genentech
HER2
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.